Treatment of menstrual migraine: utility of control of related mood disturbances.
Menstrual migraine (MM) has a prevalence in the general population of approximately 7%, although it seems to be much higher within the population of females with migraine. Episodes of MM have been reported to be longer, more intense, more disabling, less responsive to acute therapy and more prone to recurrence than those of other types of migraine. MM is demonstrated to have a bi-directional link to affective illnesses such as premenstrual dysphoric disorder and depression. There is clinical and pathophysiological evidence suggesting that the relationship between MM and affective disorders could be linked to ovarian hormones. The aim of this review is to analyze treatment strategies in patients with co-existent MM and affective disorders.
Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Andrea
A
Negro
Flavia
F
Napoletano
Luana
L
Lionetto
Francesco
F
Marsibilio
Gabriele
G
Sani
Paolo
P
Girardi
Paolo
P
Martelletti
D000700:Analgesics / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008599:Menstruation Disturbances / Q000150:complications*; D008881:Migraine Disorders / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology; D019964:Mood Disorders / Q000150:complications / Q000209:etiology / Q000628:therapy
D000700:Analgesics; D000893:Anti-Inflammatory Agents; D000928:Antidepressive Agents